Raymond James Financial Services Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-64,994	Closed	-$110K	–	2939
2018 Q3	$110K	Sell	64,994 -1,800	-3%	-$3.22K	﹤0.01%	2650
2018 Q2	$116K	Buy	66,794 +18,505	+38%	+$32K	﹤0.01%	2591
2018 Q1	$88K	Buy	48,289 +1,800	+4%	+$3.8K	﹤0.01%	2396
2017 Q4	$104K	Buy	46,489 +6,500	+16%	+$16.2K	﹤0.01%	2376
2017 Q3	$116K	Buy	39,989 +7,971	+25%	+$27.2K	﹤0.01%	2375
2017 Q2	$142K	Buy	32,018 +3,900	+14%	+$16.1K	﹤0.01%	2299
2017 Q1	$131K	Sell	28,118 -4,500	-14%	-$26.1K	﹤0.01%	2224
2016 Q4	$199K	Buy	32,618 +12,780	+64%	+$66.8K	﹤0.01%	2068
2016 Q3	$109K	Hold	19,838	–	–	﹤0.01%	2143
2016 Q2	$75K	Sell	19,838 -10,691	-35%	-$36.2K	﹤0.01%	2134
2016 Q1	$84K	Buy	+30,529	New	+$111K	﹤0.01%	1921

Other funds holding SGYP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OCM

Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Raymond James Financial Services Advisors's SGYP Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2018, closing a stake of 64,994 shares — an estimated $110K sold.

Raymond James Financial Services Advisors first reported a position in SGYP in Q1 2016 and held it in 11 quarters. The position peaked at $199K in Q4 2016. 89 funds tracked by Wall St. Rank hold SGYP as of Q4 2018.

Raymond James Financial Services Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2018 after selling out during the quarter.
Raymond James Financial Services Advisors sold 64,994 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2018, an estimated $110K.
Raymond James Financial Services Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2016 and held it in 11 quarters.
Raymond James Financial Services Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $199K in Q4 2016.
89 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.